Home  »  Business   »  What Did We Discover About Insider Trading At Stat...

What Did We Discover About Insider Trading At Statera Biopharma Inc. (NASDAQ: STAB)?

Statera Biopharma Inc. (NASDAQ:STAB) traded at $0.10 at close of the session on Tuesday, 11/22/22, made a downward move of -1.31% on its previous day’s price.

Looking at the stock we see that its previous close was $0.10 with the day’s price range being $0.0957 – $0.1032. In terms of its 52-week price range, STAB has a high of $3.60 and a low of $0.09. The company’s stock has lost about -22.21% over that past 30 days.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Statera Biopharma Inc. has a market cap of $5.17 million and is expected to release its quarterly earnings report on Oct 28, 2022.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the STAB stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 1 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Statera Biopharma Inc. (STAB) stock as a Hold, while 0 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is -20.22% off its SMA20 and -32.37% from its 50-day simple moving average. The RSI (14) is pointing at 37.98 while the volatility over the past week is 11.18% and jumps to 14.96% over the past one month. The beta value is 1.00, while the average true range (ATR) is currently pointing at 0.02. The average price target for the stock over the next 12 months is $40.00, with the estimates having a low of $40.00 and a high of $40.00. These price ends are -39900.0% and -39900.0% off the current price level respectively, although investors could be excited at the prospect of a -39900.0% if the STAB share price touches on the median price of $40.00.

Let’s briefly compare Statera Biopharma Inc. (STAB) stock to its peers. We find that current price change of -1.31% and -97.14% over the past 12 months for STAB competes that of Eli Lilly and Company (LLY), which has seen its stock price fall -0.08% in the last trading session and was 38.57% over the last one year. Another of its peers Sanofi (SNY) has gained 0.69% previous session, and was -9.36% down over the past year, while Bristol-Myers Squibb Company (BMY) was also down -0.13% in the last session, while its price remained in the green at 38.25% over the same period. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 1.36% and 1.18%, respectively, at close of the trading.

Coming back to Statera Biopharma Inc. (NASDAQ:STAB), we note that the average 3-month trading volume was 3.01 million, while that of the preceding 10-day period stands at 1.8 million. Current shares outstanding are 53.30 million.

The insiders hold 15.93% of the company’s shares while institutions hold 5.60%. The data shows that short shares as of Oct 13, 2022, stood at 2.39 million at a short ratio of 0.46. This represents a 4.70% short interest in shares outstanding on Oct 13, 2022. Shares short rose in October from the previous month at 0.76 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -95.75% down in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *